

Managing Editors

P. M. Schlag, Berlin H.-J. Senn, St. Gallen

Associate Editors

**P. Kleihues, Zürich F. Stiefel, Lausanne
B. Groner, Frankfurt A. Wallgren, Göteborg**

Founding Editor

P. Rentnick, Geneva

Hans-Jörg Senn • Ursula Kapp • Florian Otto (Eds.)

Cancer Prevention II

 Springer

Editors

Prof. Dr. med. H-J. Senn

Zentrum für Tumordiagnostik
und Prävention
Rorschacherstr. 150
9006 St. Gallen
Schweiz
hjsenn@sg.zetup.ch

Prof. Dr. med. Ursula Kapp

Zentrum für Tumordiagnostik
und Prävention
Rorschacherstr. 150
9006 St. Gallen
Schweiz
ukapp@sg.zetup.ch

Prof. Dr. med. Florian Otto

Zentrum für Tumordiagnostik
und Prävention
Rorschacherstr. 150
9006 St. Gallen
Schweiz
fotfo@sg.zetup.ch

ISBN: 978-3-540-69296-6

e-ISBN: 978-3-540-69297-3

DOI: 10.1007/978-3-540-69297-3

Library of Congress Control Number: 2008935892

ISSN. 0080-0015

© 2009 Springer-Verlag Berlin Heidelberg

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer. Violations are liable to prosecution under the German Copyright Law.

The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: The publishers cannot guarantee the accuracy of any information about dosage and application contained in this book. In every individual case the user must check such information by consulting the relevant literature.

Cover design: Frido Steinen-Broo, eStudio Calamar, Spain

Printed on acid-free paper

9 8 7 6 5 4 3 2 1

springer.com

Preface

More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention. The meeting was again organized and co-sponsored by St. Gallen Oncology Conferences (SONK).

While SONK has been extremely successful in organizing large international congresses on “Primary Therapy of Early Breast Cancer” as well as “Supportive Care in Cancer” for more than 20 years, the idea of promoting interdisciplinary, clinically oriented meetings on cancer prevention is a more recent and not yet generally accepted and welcomed concept in modern oncology. Since today’s medical expenses are soaring and medical research budgets are stagnating or even being cut, neither politicians nor industry is willing to risk an additional unpredictable channel of expenses, such as that demanded by clinical cancer prevention efforts!

In Switzerland—and we fear in many other parts of the globe—some 97%–98% or even a greater percentage of health budgets is spent for curative and palliative/rehabilitative medicine. Since a meager 2%–3% of national health budgets is for preventive medicine, even less than that proportion is specifically allocated for cancer prevention. When the money for “curing and caring” for the diseased populace runs short, there is likely not much left for partly controversial disease prevention in the (still) healthy part of the population. Although this might be an extremely short-sighted view, it is noticeably prevalent with health politicians and even with large parts of the medical profession, at least in Continental Europe, today.

Despite this ironic situation, we have decided to keep trying to promote the promising field of clinical cancer prevention by organizing biannual international conferences in view of the accumulating interactions between molecular genetics and biology, epidemiology and clinical cancer prevention. Together with a growing number of scientific and professional partners, we intend to periodically set the stage for a comprehensive scientific discussion forum critically analyzing the development of more efficient and more acceptable primary and secondary cancer prevention approaches for the future. It is rather unfortunate that the oncology-oriented pharmaceutical industry—especially in Europe—is not yet willing or prepared to support this fascinating field, especially chemoprevention, by more appropriate research involvement and educational funding.

It was our privilege to co-organize this meeting again on behalf of the International Society of Cancer Prevention (ISCaP, New York, NY, USA) together with the European School of Oncology (ESO, Milan, Italy) and the European Society of Medical Oncology (ESMO, Lugano). For this fifth prevention conference in March 2008 we were able to generate some new and greatly welcomed additional and “neutral” supporters or sponsors: Cancer Research UK (CRUK, London, UK), the Union Internationale Contre le Cancer (UICC, Geneva, Switzerland), the European Association of Cancer Research (EACR, Nottingham, UK), the American Cancer Society (ACS, Atlanta, GA, USA), and the Swiss Cancer League (Bern, Switzerland). Very little financial support was provided by industry. The local organizers were Prof. Hans-Jörg Senn, MD, Prof. Ursula Kapp, MD, and Prof. Florian Otto, all from the prevention-oriented Tumor Center ZeTuP in St. Gallen, Switzerland.

This 2008 St. Gallen International Cancer Prevention Conference—in contrast to the previous meetings in 2004 and 2006—was primarily targeted to primary prevention, and even more specifically at the chemoprevention of major cancer types such as breast, colorectal, cervical, and lung. Besides the traditional sessions on health politics and organ-site-oriented cancer prevention efforts, we tried for the first time to upgrade this 2008 conference with a well-prepared consensus session on the present state of the art of chemoprevention of colorectal cancer by aspirin and nonsteroidal antiinflammatory drugs (NSAIDs), chaired by Prof. Jack Cuzick, president of ISCaP and director of the Wolfson Institute of Preventive Medicine in London, UK, and by Dr. Peter Greenwald, the director of the prevention branch of the NCI in Bethesda, MD, USA.

This consensus of the use of aspirin and NSAIDs in chemoprevention of colorectal cancers will be published separately in a major oncology journal. As is the tradition, the majority of the invited expert contributions to the conference are published in this internationally well-known series, *Recent Results in Cancer Research*, by Springer. We hope you enjoy its multifaceted content.

Already the organizers invite dedicated scientists, epidemiologists, and clinicians interested in primary and secondary (clinical) cancer prevention to the next international cancer prevention conference, which will be held in St. Gallen, 18–20 March 2010.

Hans-Jörg Senn, Ursula Kapp, Florian Otto

Contents

Part I Cancer Prevention and Health Politics

1 Do We Make Optimal Use of the Potential of Cancer Prevention?	3
Peter Greenwald and Barbara K. Dunn	
1.1 Introduction.....	4
1.2 Lifestyle Interventions	4
1.3 Medical Interventions	7
1.4 The Changing Landscape of Clinical Studies	7
1.5 Prevention Clinical Trials.....	9
1.6 Biomarkers for Cancer Prevention.....	11
1.7 Systems Biology	13
1.8 Future Directions for Attaining Optimal Impact in Cancer Prevention.....	14
References.....	15
2 Predictors of Successful Cancer Prevention Programs	19
Franz Porzsolt, Anita Kirner, and Robert M. Kaplan	
2.1 Introduction.....	19
2.2 Methods.....	20
2.3 Results.....	20
2.3.1 Quality of Prevention Programs.....	20
2.3.2 Recommended Prevention Programs	24
2.3.3 Critical Appraisal of Traditional Selection Criteria	25
2.3.4 Incidence in Primary and Secondary Prevention	26
2.4 Discussion	27
References.....	29

3	Cancer Prevention in the Developing World: Mission Impossible?	33
	Franco Cavalli	
3.1	A Changing Pattern	33
3.2	A Possible Roadmap	35
3.3	A Provisional Conclusion	37
	References	38
4	Is Cancer Prevention Ever Going to Be Profitable?	41
	Thomas D. Szucs and Konstantin J. Dedes	
4.1	Introduction.....	41
4.2	What Will Be the Economic Future of Cancer Care?	42
4.3	How Do We Determine “Value for Money”?.....	42
4.3.1	Types of Formal Economic Evaluations.....	45
4.3.2	Applying Cost-Effectiveness Evaluations.....	46
4.4	So Will Cancer Prevention Ever Be Profitable?	46
	References.....	47
 Part II Cancer Prevention: The Scientific-Epidemiological Base		
5	Energy Metabolism, Cancer Risk, and Cancer Prevention	51
	Michael Pollak	
	References	53
6	Promises and Limitations of Biomarkers	55
	David F. Ransohoff	
6.1	Promise Versus Product.....	55
6.2	Threats to Validity from Chance and Bias	55
6.3	Addressing Current Problems	56
6.3.1	Every Study Should Be Reliable.....	56
6.3.2	Drug Research Versus Marker Research.....	56
6.3.3	Role of Specimens	57
6.3.4	Shortcuts: By Using Already-Collected Specimens	57
6.4	Conclusion	58
	References.....	58
 Part III Cancer Prevention, Tobacco and Nutrition		
7	The EPIC Study: An Update	63
	Paolo Vineis and Elio Riboli	
7.1	The EPIC Study Design.....	63
7.1.2	Exposure Variables.....	64
7.1.3	Follow-Up and Case Ascertainment.....	64
7.1.4	Biological Samples	65

7.2	Recent Find ings on Diet and Biomarkers	65
7.2.1	Fibres, Meat Intake and Colorectal Cancer.....	65
7.2.2	Cancer, Hormones and BMI	65
	References.....	68
8	Anti-angiogenic Properties of Chemopreventive Drugs:	
	Fenretinide as a Prototype	71
	Ilaria Sogno, Roberta Venè, Cristina Sapienza, Nicoletta Ferrari, Francesca Tosetti, and Adriana Albini	
8.1	Molecular Regulators of Angiogenesis as Drug Targets for Chemoprevention.....	71
8.2	Angioprevention: When Cancer Chemoprevention Meets Angiogenesis	72
8.3	Retinoids and 4HPR as Angiopreventive Molecules	73
	References.....	74
9	Retinoids and Breast Cancer Prevention	77
	Bernardo Bonanni and Matteo Lazzeroni	
9.1	Introduction.....	77
9.2	Clinical Trials.....	78
9.3	Fenretinide and Ovarian Cancer	80
9.4	Conclusions and Future Perspectives.....	80
	References.....	81
 Part IV Cancer Prevention, Genetics and Vaccines		
10	Cancer Prevention by Vaccination Against Hepatitis B	85
	Mei-Hwei Chang	
10.1	Introduction.....	85
10.2	Cancer Prevention by Vaccination	86
10.2.1	Advantage of Cancer Prevention by Vaccination.....	86
10.3	Chronic Hepatitis B Virus Infection and Hepatocellular Carcinoma.....	87
10.4	Strategies to Prevent Viral Hepatitis B-Associated Hepatocellular Carcinoma	87
10.4.1	Primary Prevention by Immunoprophylaxis	87
10.4.2	Treatment of Viral Hepatitis/Cirrhosis.....	87
10.4.3	Chemoprevention.....	87
10.4.4	Liver Transplantation for End-Stage Cirrhosis.....	88
10.5	Cancer Prevention by Hepatitis B Vaccination	88
10.6	Why Should the Hepatitis B Vaccine Be Given at Birth to Prevent Cancer?	88
10.7	Hepatitis B Immunoprophylaxis Program	89
10.8	Impact of Universal Hepatitis B Immunization on Chronic Infection.....	90

10.9	Demonstration of the Efficacy of Cancer Prevention by Hepatitis B Vaccination.....	90
10.10	Problems in Preventing Liver Cancer by Vaccination.....	90
10.10.1	Inadequate Resources	91
10.10.2	Ignorance or Poor Compliance Due to Anxiety to the Safety of Vaccine	91
10.10.3	Vaccine Failure or Nonresponders	91
10.10.4	No Effective Vaccine Available	92
10.11	Conclusions and Future Prospects	92
10.11.1	Hepatoma Control.....	92
10.11.2	Implication to the Control of Other Cancers	92
	References.....	92

Part V Cancer Prevention and Target Organs I: Breast Cancer

11	Energy Restriction for Breast Cancer Prevention.....	97
	Anthony Howell, Mary Chapman, and Michelle Harvie	
11.1	Introduction.....	97
11.2	Risk Factors for Breast Cancer	98
11.3	Effect of Weight and Weight Gain and Exercise Deficiency on Breast Cancer Risk.....	98
11.4	Mechanism of Weight Gain and Exercise Deficiency on Risk.....	99
11.5	Chronic Energy Restriction Reduces Cancer Risk	99
11.6	Intermittent Energy Restriction Also Reduces Breast Cancer Risk	100
11.7	Mechanism of the Effect of CER and IER	100
11.8	Energy Restriction Mimetic Agents.....	101
11.9	Inhibitors of Glycolysis.....	102
11.10	Inhibitors of Lipid Synthesis	103
11.11	Activation of AMP-Activated Protein Kinase.....	104
11.12	Stimulation of Mitochondrial Activity and Fat Oxidation	104
11.13	Activation of SIRT1	104
	Summary and Conclusions	105
	References.....	105
12	The Use of Tamoxifen and Raloxifene for the Prevention of Breast Cancer	113
	D. Lawrence Wickerham, Joseph P. Costantino, Victor G. Vogel, Walter M. Cronin, Reena S. Cecchini, Leslie G. Ford, and Norman Wolmark	
12.1	Introduction.....	114
12.2	The Study of Tamoxifen and Raloxifene	114
12.3	Results.....	115
12.3.1	Invasive Breast Cancer.....	115

12.3.2	Noninvasive Breast Cancer	116
12.3.3	Other Secondary Endpoints	116
12.4	Discussion	117
	References.....	118
13	Prevention of ER-Negative Breast Cancer	121
	Yuxin Li and Powel H. Brown	
13.1	SERMs and Aromatase Inhibitors	122
13.2	Novel Agents for the Prevention of ER-Negative Breast Cancer	123
13.3	Retinoids	124
13.4	Vitamin D Receptor	127
13.5	EGFR/Tyrosine Kinase Inhibitors.....	127
13.6	COX-2 Inhibitors	129
13.7	Statins	130
13.8	Combination Chemoprevention	130
13.9	Conclusion	131
	Acknowledgement	131
	References.....	132
14	Exogenous and Endogenous Hormones, Mammographic Density and Breast Cancer Risk: Can Mammographic Density Be Considered an Intermediate Marker of Risk?	135
	Susen Becker and Rudolf Kaaks	
14.1	Introduction.....	135
14.2	General Determinants and Correlates of Mammographic Density	137
14.3	Sex Steroid Hormones and Breast Density.....	137
14.3.1	Postmenopausal Hormone Replacement Therapy	137
14.3.2	Endogenous Sex Hormones	138
14.4	Selective Estrogen Receptor Modulators.....	142
14.5	Aromatase Inhibitors	143
14.6	Gonadotropin-Releasing Hormone Agonists.....	144
14.7	IGF-I and Its Binding Proteins	145
14.8	Prolactin	146
14.9	Discussion.....	149
	References.....	150
Part VI	Cancer Prevention and Target Organs II: Cancer of the Digestive Tract	
15	Chemoprevention of Oesophageal Cancer and the AsPECT Trial.....	161
	Debasish Das, Andrew P. Chilton, and Janusz A. Jankowski	
15.1	Introduction.....	161
15.2	Barrett's Oesophagus	162

15.3	Need for Chemoprevention Approach Rather Than Surveillance	162
15.4	The AspECT Trial	163
15.5	Trials Related to AspECT	164
15.6	The Evidence Base for Using Aspirin and Esomeprazole	165
15.6.1	Aspirin	165
15.6.2	Esomeprazole	165
15.7	Conclusion	167
	References	167

Part VII Cancer Prevention and Target Organs III: Prostate Cancer

16	Review of Diagnostic Markers for Prostate Cancer	173
	Fritz H. Schröder	
16.1	Characteristics of PSA-Driven Screening	174
16.1.1	PSA and Cancer Aggressiveness	175
16.2	How to Improve on PSA in the Detection of Prostate Cancer?	176
16.2.1	PSA Use in Men Less Than 50 Years Old	176
16.3	Selective Detection of Aggressive Prostate Cancer	178
16.3.1	PSA Velocity	179
16.4	Needs and Expected Future Developments	179
16.5	Conclusions	180
	References	180
17	Selenium and Vitamin E Cancer Prevention Trial: A Nutrient Approach to Prostate Cancer Prevention	183
	Barbara K. Dunn, Anne Ryan, and Leslie G. Ford	
17.1	Introduction	183
17.1.1	A Preventive Approach to the Problem of Prostate Cancer	183
17.1.2	SELECT: Selection of Study Interventions	184
17.2	SELECT: Study Design	186
17.2.1	Study Objectives	186
17.2.2	Selection of Study Agents	186
17.2.3	Study Cohort	187
17.2.4	Study Design	187
17.2.5	Statistical Considerations	188
17.2.6	Evaluation of Prostate Cancer Endpoint	189
17.2.7	SELECT in Contrast to PCPT	189
17.2.8	Ancillary Studies	189
17.3	Study Implementation	190
17.4	Future Challenges in the Conduct of SELECT	190
	References	191

18 Prostate Cancer Prevention by Short-Term Anti-androgens: The Rationale Behind Design of Pilot Studies	195
Tim Oliver, Attila Lorincz, and Jack Cuzick	
18.1 Introduction.....	195
18.2 Modern Evidence of a Contributory Role for Sexually Acquired Infection to Causation of Prostate Cancer But Lack of Specificity of Organism.....	196
18.3 Modern Ideas on the Role of Inflammation as Causative of Malignant Transformation and Its Relevance to Prostate Cancer	197
18.4 PSA Screening and Impact on Over-Diagnosis of Prostate Cancer.....	198
18.5 Evidence of Harm from Prostate Biopsy.....	199
18.6 Lack of Evidence of Major Therapeutic Gain from Current Approaches to Radical Treatment of Prostate Cancer	199
18.7 Possible New Approaches to Chemo-prevention of Prostate Cancer.....	200
18.8 Choice of Patient Populations for Chemo-prevention Studies.....	200
18.8.1 Patients with Low-Grade Prostate Cancer Volunteering for Surveillance Protocols.....	200
18.8.2 Patients with Persistent PSA Elevation After a Negative Biopsy Developing Prostate Cancer	201
18.8.3 Patients with STDs.....	201
18.8.4 Patients with Male Factor Infertility	201
18.9 Conclusion	202
References.....	202

Part VIII Cancer Prevention: Metabolic Aspects

19 Anti-angiogenic Activity of a Novel Class of Chemopreventive Compounds: Oleanic Acid Terpenoids	209
Ilaria Sogno, Nicola Vannini, Girieca Lorusso, Rosaria Cammarota, Douglas M. Noonan, Luca Generoso, Michael B. Sporn, and Adriana Albini	
19.1 Introduction.....	210
19.2 Angioprevention and Anti-angiogenic Therapy	210
19.3 Triterpenoids: New Promising Angiogenesis Regulators	211
References.....	212

Part IX Aspirin and NSAIDs in Cancer Prevention: Attempts at an International Consensus		
20	Pharmacologic Effects of NSAIDs and Implications for the Risks and Benefits of Long-Term Prophylactic Use of Aspirin to Prevent Cancer	215
	Michael J. Thun and Bonny Blackard	
20.1	Introduction.....	215
20.2	Risk–Benefit Considerations	219
20.3	Conclusions.....	220
	References.....	220
21	Aspirin and NSAIDs for the Prevention of Colorectal Cancer	223
	John A. Baron	
21.1	Introduction.....	223
21.2	Colorectal Neoplasia: Observational Studies	224
21.3	Clinical Trial Data: Sporadic Colorectal Neoplasia.....	225
21.4	Special Populations.....	226
	References.....	227
22	Aspirin and Cancer Risk: A Summary Review to 2007	231
	Cristina Bosetti, Silvano Gallus, and Carlo La Vecchia	
22.1	Introduction.....	231
22.2	Materials and Methods	231
22.3	Results.....	232
22.3.1	Colon and Rectal Cancer	232
22.3.2	Other Digestive Tract Cancers	238
22.3.3	Lung Cancer.....	243
22.3.4	Breast and Ovarian Cancers.....	243
22.3.5	Prostate Cancer	244
22.3.6	Bladder and Kidney Cancers	244
22.3.7	Lymphatic and Haematopoietic Cancers	244
22.4	Discussion.....	245
	References.....	245

List of Contributors

Adriana Albini, PhD

IRCCS MultiMedica
Oncology Research
Via Fantoli 16/15
20138 Milan
Italy

John A. Baron, MD MS MSc

Evergreen Center, Biostatistics and
Epidemiology
Suite 300, 46 Centerra Parkway
Lebanon, NH 03756
USA

Susen Becker, Dr.

German Cancer Research Center (DKFZ)
Im Neuenheimer Feld 280
69120 Heidelberg
Germany

Bonny Blackard, BSPH

Epidemiology and Surveillance Research
American Cancer Society
250 Williams Street, NW
Atlanta, GA 30303-1002
USA

Bernardo Bonanni, MD

Division of Cancer Prevention and
Genetics
European Institute of Oncology
Via Ripamonti 435
20141 Milan
Italy

Cristina Bosetti, ScD

Istituto di Ricerche Farmacologiche “Mario
Negri”
Via Giuseppe La Masa 19
20156 Milan
Italy

Powel H. Brown, Prof. Dr. MD PhD

Lester and Sue Smith Breast Center
Baylor College of Medicine
Dan L. Duncan Cancer Center
One Baylor Plaza, BCM 600
Houston, TX 77030
USA

Rosaria Cammarota, PhD

IRCCS MultiMedica
Oncology Research
Via Fantoli 16/15
20138 Milan
Italy

Franco Cavalli, Prof. Dr. MD

IOSI Ospedale San Giovanni
 Servizio Oncologico
 6500 Bellinzona
 Switzerland

Reena S. Cecchini, MS

Operations Center
 National Surgical Adjuvant Breast and
 Bowel Project (NSABP)
 Four Allegheny Center, 5th Floor
 Pittsburgh, PA 15212, USA
 and
 Department of Biostatistics
 Graduate School of Public Health
 University of Pittsburgh
 201 North Craig Street, Suite 350
 Pittsburgh, PA 15213
 USA

Mei-Hwei Chang, MD

National Taiwan University Hospital
 No. 7, Chung-Shan S. Road
 100 Taipei
 ROC Taiwan

Mary Chapman

The Genesis Prevention Centre
 University Hospital of South Manchester
 Manchester M20 9LT
 UK

Andrew P. Chilton, Dip Pharm FRCP

Department of Gastroenterology
 Kettering General Hospital
 Rothwell Road
 Kettering, Northants NN16 8UZ
 Kettering
 UK

Joseph P. Costantino, Dr. PH

Operations Center
 National Surgical Adjuvant Breast and
 Bowel Project (NSABP)
 Four Allegheny Center, 5th Floor
 Pittsburgh, PA 15212
 USA

and

Department of Biostatistics
 Graduate School of Public Health
 University of Pittsburgh
 Pittsburgh, PA 15261
 USA

Walter M. Cronin, MPH

Operations Center
 National Surgical Adjuvant Breast and
 Bowel Project (NSABP)
 Four Allegheny Center, 5th Floor
 Pittsburgh, PA 15212
 USA
 and
 Department of Biostatistics, Graduate
 School of Public Health
 University of Pittsburgh
 201 North Craig Street, Suite 350
 Pittsburgh, PA 15213
 USA

Jack Cuzick, PhD

Wolfson Institute of Preventive
 Medicine
 Queen Mary University London
 Charterhouse Square
 London EC1M 6BQ
 UK

Debasish Das, MD MRCP(UK)

Digestive Disease Centre
 Leicester Royal Infirmary
 Infirmary Sq.
 Leicester, LE1 5WW
 UK

Konstantin J. Dedes, MD

Division of Gynecology
 Department of Obstetrics
 and Gynecology
 University Hospital of Zurich
 8091 Zurich
 Switzerland

Barbara K. Dunn, MD PhD

National Cancer Institute NIH
Division of Cancer Prevention
EPN 2056
6130 Executive Blvd.
Bethesda, MD 20852
USA

Nicoletta Ferrari, PhD

Molecular Oncology and Angiogenesis
Laboratory
National Cancer Research
Institute (IST)
Largo R. Benzi, 10
16132 Genoa
Italy

Leslie G. Ford, MD

Division of Cancer Prevention
National Cancer Institute NIH
EPN 2046, 6130 Executive Blvd.
Bethesda, MD 20892
USA

Silvano Gallus, ScD

Istituto di Ricerche Farmacologiche
“Mario Negri”
Via Giuseppe La Masa 19
20156 Milan
Italy

Peter Greenwald, MD Dr. PH

National Cancer Institute NIH
Division of Cancer Prevention
Room 2040
6130 Executive Blvd.
Bethesda, MD 20892
USA

Michelle Harvie

The Genesis Prevention Centre
University Hospital
of South Manchester
Manchester M20 9LT
UK

Anthony Howell, Prof. Dr.

Christie Hospital NHS Trust
University of Manchester
CRUK Department of Medical Oncology
Wilmslow Road
Manchester M20 4BX
UK

Janusz A Jankowski, Prof.

James Black Senior Clinical Fellow
Department of Clinical Pharmacology
University of Oxford
Radcliffe Infirmary
Woodstock Road
Oxford OX2 6HA
UK

Rudolf Kaaks, Prof. Dr.

German Cancer Research Center (DKFZ)
Im Neuenheimer Feld 280
69120 Heidelberg
Germany

Robert M. Kaplan, PhD

Department of Health Services
UCLA School of Public Health
PO Box 951772
Room 31-293C CHS
Los Angeles, CA 90025-1772
USA

Anita Kirner

Clinical Economics
University of Ulm
Frauensteige 6
89075 Ulm
Germany

Carlo La Vecchia, MD

Mario Negri Institute for Pharmacological
Research
Laboratory of General Epidemiology
Via La Masa 19
20156 Milan
Italy
and

Istituto di Statistica Medica e Biometria
“G.A. Maccacaro”
Università degli Studi di Milano
Via Venezian 1
20133 Milan
Italy

Matteo Lazzeroni, MD

Università degli Studi di Roma Tor Vergata
Via Montpellier, 1
00133 Rome
Italy

Yuxin Li

Lester and Sue Smith Breast Center
Baylor College of Medicine
Dan L. Duncan Cancer Center
One Baylor Plaza, BCM 600
Houston, TX 77030
USA

Attila Lorincz, PhD

Wolfson Institute of Preventive Medicine
Queen Mary University London
Charterhouse Square
London EC1M 6BQ
UK

Girieca Lorusso, PhD

IRCCS MultiMedica
Oncology Research
Via Fantoli 16/15
20138 Milan
Italy

Douglas M. Noonan, PhD

Laboratory of Molecular Biology and
Tumor
University of Insubria
Via O. Rossi, 9
21100 Varese
Italy

Tim Oliver

Wolfson Institute of Preventive Medicine
Queen Mary University London
Charterhouse Square
London EC1M 6BQ
UK

Michael Pollak, Prof. Dr. MD FRCPC

General Jewish Hospital
Medicine and Oncology
3755 Côte-St. Catherine Rd.
Montreal QC H3T1E2
Canada

Franz Porzolt, MD PhD

Clinical Economics
University of Ulm
Frauensteige 6
89075 Ulm
Germany

David F. Ransohoff, Prof. MD

Professor of Medicine
and Clinical Professor of Epidemiology
University of North Carolina at Chapel Hill
3203 Kerr Hall
27599-7360 Chapel Hill, NC
USA

Elio Riboli, MD PhD

Imperial College London
Faculty of Medicine
Department of Epidemiology
and Public Health
Norfolk Place
London W2 1PG
UK

Anne Ryan

National Cancer Institute NIH
Division of Cancer Prevention
EPN 2022
6130 Executive Blvd.
Bethesda, MD 20852
USA

Cristina Sapienza, PhD

Molecular Oncology and Angiogenesis
Laboratory
National Cancer Research Institute (IST)
Largo R. Benzi, 10
16132 Genoa
Italy

Fritz H. Schröder, MD PhD

Professor of Urology
Erasmus MC
University Medical Center
P.O. Box 2040
3000 CA Rotterdam
The Netherlands

Ilaria Sogno, PhD

IRCCS MultiMedica
Oncology Research
Via Fantoli 16/15
20138 Milan
Italy

Michael B. Sporn, MD PhD

IRCCS MultiMedica
Oncology Research
Via Fantoli 16/15
20138 Milan
Italy

Thomas D. Szucs, MD MPH MBA LLM

Institute of Social and Preventive Medicine
University of Zurich
Hirschengraben 84
8001 Zurich
Switzerland

Michael J. Thun, MD MS

Epidemiology and Surveillance Research
American Cancer Society
250 Williams Street, NW
Atlanta, GA 30303-1002
USA

Francesca Tosetti, PhD

Molecular Oncology and Angiogenesis
Laboratory
National Cancer Research Institute (IST)
Largo R. Benzi, 10
16132 Genoa
Italy

Nicola Vannini, PhD

IRCCS MultiMedica
Oncology Research
Via Fantoli 16/15
20138 Milan
Italy

Roberta Venè, PhD

Molecular Oncology and Angiogenesis
Laboratory
National Cancer Research Institute (IST)
Largo R. Benzi, 10
16132 Genoa
Italy

Paolo Vineis, Prof. MD MPH

Imperial College London
St. Mary's Campus
Environmental Epidemiology
Norfolk Place
London W2 1PG
UK

Victor G. Vogel, MD

Operations Center
National Surgical Adjuvant Breast
and Bowel Project (NSABP)
Four Allegheny Center, 5th Floor
Pittsburgh, PA 15212
USA

D. Lawrence Wickerham, MD

Operations Center
National Surgical Adjuvant Breast and
Bowel Project (NSABP)
Four Allegheny Center, 5th Floor
Pittsburgh, PA 15212
USA

Norman Wolmark, MD

Allegheny General Hospital
320 East North Avenue
Pittsburgh, PA 15212
USA

Part I

**Cancer Prevention
and Health Politics**

Do We Make Optimal Use of the Potential of Cancer Prevention?

1

Peter Greenwald and Barbara K. Dunn

Abstract Three decades of intensive experimental and clinical research on cancer prevention have yielded an impressive body of scientific knowledge about cancer epidemiology, causation, and preventative measures. Despite our increased understanding in these critical areas, this knowledge is not being translated adequately into initiatives that will impact public health. The recent release of the World Cancer Research Fund/American Institute for Cancer Research report on diet and lifestyle strategies for cancer prevention—grounded in an evidence-based, systematic review of the published literature—is a strong acknowledgment of the benefits of a lifestyle approach to reduce cancer risk. The report also emphasizes the need to increase basic nutritional science research to make optimal use of the knowledge gained in the past three decades. Medical approaches—represented by chemoprevention clinical trials—also have become more focused based on results from basic science leads. The expansion of preclinical chemoprevention studies and greater attention to “first-in-human” prevention trials that safely shorten the timeline for new drug development are needed. The development

of a prevention focus for what the U.S. Food and Drug Administration calls “exploratory investigational new drug studies” and what investigators at the National Cancer Institute are calling “phase 0” clinical trials will contribute to the decision-making involved in designing larger cancer prevention clinical trials. Past achievements in phase III prevention clinical trials—such as the Prostate Cancer Prevention Trial, the Breast Cancer Prevention Trial, and the Study of Tamoxifen and Raloxifene—have provided early successes as evidence of the potential for public benefit to be derived from this research. Nevertheless, the application of these findings to clinical practice and the design of future prevention trials remains a challenge. Current strategies include the refinement of risk assessment models for several major cancers. Additional initiatives, based on emerging basic and clinical research, involve the development of potential biomarkers for cancer risk and early detection by the National Cancer Institute’s Early Detection Research Network. Although a recent progress report indicates that biomarkers of cancer susceptibility and exposure have been identified, continued work is needed to validate such markers for clinical use. Using this information optimally for prevention through lifestyle changes or medical interventions will

Peter Greenwald (✉)
E-mail: hursens@mail.nih.gov

demand commitments from public and private research institutions. Another area of emerging research is the development of a systems biology approach to cancer prevention. This will demand the creation of multidisciplinary teams of researchers from biological sciences, informatics and engineering scientists, and researchers from many fields not generally focused on disease prevention. To facilitate this and other new approaches, and to make effective use of information and strategies for cancer prevention, intensive training efforts must be implemented to develop the next generation of basic and clinical scientists—and physician researchers—capable of working in a cross- and multidisciplinary research environment. Training current researchers in new approaches will add efficiency to their combined research experiences.

1.1 Introduction

For most of the past 35 years, trends in the incidence and mortality rates of all major cancers in the United States showed steady increases. This pattern changed in the 1990s when decreases started to emerge (National Cancer Institute 2007), with mortality rates declining at approximately half that of incidence rates (Ries et al. 2007). While for some of the most common types of cancer in the United States—breast, prostate, colorectal, and lung—considerable progress has been made regarding mortality and incidence, in specific cancer types in some population groups (e.g., lung cancer in women and prostate cancer among African Americans) such progress is not evident.

The role of cancer prevention underlies much of this observed decrease in cancer incidence and mortality. For three decades, an impressive body of research has accumulated indicating that lifestyle and medical prevention

strategies can have a major impact on cancer incidence and mortality. Nevertheless, doubt exists as to whether clinicians and other health professionals are making optimal use of existing knowledge regarding cancer prevention strategies. Cancer prevention offers a key opportunity to reduce the disease burden both on individuals and on the healthcare system. To achieve the maximum benefit from cancer reduction, major initiatives in prevention must include both lifestyle and chemoprevention approaches.

The following sections discuss current research on lifestyle and medical intervention studies—as well as selected molecular and genetic studies—in cancer prevention. In addition, a review is presented of progress in several areas: the translation of research findings into public benefit; new approaches for designing and developing clinical trials to target individuals most likely to benefit from trial findings; and suggestions for increased and novel approaches to training with a goal of producing the multidisciplinary researchers needed for working with emerging high-throughput and “-omic” (e.g., genomic, proteomic, transcriptomic, and metabolomic) technologies.

1.2 Lifestyle Interventions

Preventing cancer through lifestyle modifications and other interventions has received increased attention in the past decade as more is understood about the role of nutrition, weight gain/loss, and the level of physical activity and cancer risk. Since the Doll and Peto quantitative analysis of estimates of avoidable cancer risks in 1981 (Doll and Peto 1981), accumulating evidence suggests that lifestyle may contribute to as much as 70% of cancer cases; nutrition alone is a factor in at least 30%–40% of cancers. Adopting lifestyle modifications—in areas involving diet,

physical activity, use of tobacco, and weight control—offers a major approach to cancer prevention for most individuals. In the past, however, apart from the avoidance of tobacco, limited convincing evidence had been available to make recommendations regarding these lifestyle areas. This situation changed rapidly as findings from basic, epidemiological, and clinical research began to fill in gaps in our knowledge. For example, the recent release of *Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective* (World Cancer Research Fund 2007)—the 2007 expert report developed and published by the World Cancer Research Fund (WCRF) and the American Institute of Cancer Research (AICR)—highlighted the role of lifestyle on cancer prevention. The report is evidence-based and draws from a substantial body of cancer prevention literature published in the past decade.

What distinguishes this recent report from past documents is the utilization of increasingly available data from controlled clinical trials and large prospective studies on nutrition and cancer.

Table 1.1 highlights the recommendations from the report, which incorporates government recommendations (U.S. Department of Health and Human Services 2005). Table 1.2 highlights the report's findings on lifestyle factors and decreased or increased risk of cancer by cancer site. The inclusion of a factor in Table 1.2 indicates that the authors of the report found the evidence to be either "probable" or "convincing" for its use in assessing the level of cancer risk. "Convincing" is the highest level of evidence for a recommendation, based on the judgment that the evidence will be unlikely to change over time and is based on congruent results from at least two independent cohorts. The underlying evidence has favorable attributes including: (1) no substantial heterogeneity in the data; (2) plausible dose responses; (3) consistent evidence from laboratory studies; and (4) accountability for error. Taken in totality, the evidence suggests that specific lifestyle changes could have a major impact on cancer prevention if optimal use of the information became part of physician practice and public policy recommendations.

Table 1.1 WCRF/AICR (2007) recommendations adapted from *Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective*, incorporating 2005 U.S. dietary guidelines

General recommendations for cancer prevention

1. Be as lean as possible without becoming underweight (goal: BMI 21–23)
2. Be physically active for at least 30min every day
3. Avoid sugary drinks. Limit consumption of energy-dense foods (particularly processed foods high in added sugar, or low in fiber, or high in fat)
4. Eat more of a variety of vegetables, fruits, whole grains and legumes such as beans
5. Limit consumption of red meats (such as beef, pork, and lamb) and avoid processed meats
6. If consumed at all, limit alcoholic drinks to 2 for men and 1 for women a day
7. Limit consumption of salty foods and foods processed with salt (sodium). Avoid moldy cereals (grains) or legumes
8. Aim to meet nutritional needs through diet alone. Do not use supplements to protect against cancer

Special population recommendations

9. New mothers ideally should breastfeed exclusively for up to 6 months and then add other liquids and foods
10. Cancer survivors after treatment should follow the recommendations for cancer prevention

Table 1.2 Convincing evidence of decreased or increased risk of cancer by cancer site and lifestyle factor (*Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective*; WCRF/AICR 2007)

Lifestyle factors with probable and/or convincing decreased risk of cancer^a	
Colorectum	Foods containing dietary fiber, garlic, milk, calcium supplements, increased physical activity (probable evidence)
Mouth, pharynx, larynx	Non-starchy vegetables, fruits, foods containing carotenoids (probable evidence)
Esophagus	Non-starchy vegetables, fruits, foods containing beta-carotene (probable evidence)
Stomach	Non-starchy vegetables, <i>Allium</i> vegetables, fruits (probable evidence)
Lung	Fruits, foods containing carotenoids (probable evidence)
Pancreas	Foods containing folate (probable evidence)
Prostate	Foods containing lycopene, foods containing selenium, selenium supplements (probable evidence)
Breast	Lactation
Lifestyle factors with probable and convincing increased risk of cancer^a	
Liver	Aflatoxins
Colorectum	Red meat, processed meat, alcoholic drinks (men only), body fatness, abdominal fatness, adult-attained height
Lung	Arsenic in drinking water, beta-carotene supplements
Mouth, pharynx, larynx	Alcoholic drinks
Esophagus	Alcoholic drinks, body fatness
Breast, premenopausal	Alcoholic drinks (probable evidence)
Breast, post-menopausal	Alcoholic drinks, body fatness, adult-attained height
Pancreas	Body fatness
Endometrial	Body fatness
Kidney	Body fatness

^a Evidence is convincing unless otherwise noted as probable

The potential for research opportunities geared toward improving the science of nutrition and cancer emerged directly from this report. These opportunities include integrating the recommendations on chronic diseases, and on promoting positive health and well-being. The relationship between causation and prevention should be elucidated and a revived look at descriptive studies, such as those on migrant populations, is needed.

Other important research gaps include studies on determinants of rapid growth and early puberty; dietary energy restriction in humans; food systems and dietary patterns; foods common in traditional diets; populations in parts of the

world for which cancer is uncommon; and follow-up studies of exclusively breastfed children. There also is a need to develop standard definitions of physical activity and processed meat, and to determine when in the course of life specific preventative interventions are most effective. WCRF and AICR have committed to regularly updating the report as new evidence is published. (A summary and complete report can be found at <http://www.wcrf.org/research/fnat-poc.lasso>.)

Other important findings of the past decade relating lifestyle interventions to cancer prevention include the emerging recognition of obesity as a major factor in cancer etiology. Calle and

colleagues suggested that being overweight or obese contributes to 15%–20% of cancer deaths; given the increasing numbers of obese Americans, the promotion of weight control has potential as a broadly effective lifestyle approach to cancer prevention (Calle et al. 2003). Regular, moderate physical activity also has been associated with reduced risk of various cancers, including colon cancer (Samad et al. 2005).

A preventative approach of lifestyle modifications that targets diet, physical activity, and weight control is likely to impact morbidity and mortality due to cancer.

1.3 Medical Interventions

Unlike lifestyle interventions, which are generally designed to target cancer risk broadly in populations, medical interventions are more specific in that they focus on limited cancer types in individuals or subpopulation groups that are at increased risk of developing those cancers. Both types of intervention, however, are important for overall reductions in cancer morbidity and mortality. The field of study involving the medical intervention approach to cancer prevention is maturing as it incorporates knowledge generated from basic, epidemiological, and clinical research. In particular, the increased understanding of the molecular, genetic, and epigenetic processes that contribute to or prevent carcinogenesis feeds directly into the formulation of medical preventative interventions. New approaches for designing and implementing cancer prevention clinical trials will also directly affect investigators' ability to provide evidence of benefits (or lack of benefit) for medical interventions. The use of emerging technologies and the collaborative efforts of multidisciplinary research teams are expected to accelerate the pace of new discoveries.

1.4 The Changing Landscape of Clinical Studies

The use of lifestyle or medical interventions ideally depends on their evaluation in clinical trials—preferably testing each intervention in relation to a control group in a randomized controlled trial (RCT). Before cancer prevention agents—nutrient- and non-nutrient-based—can be tested in RCTs, however, they must undergo testing in a phased clinical trial regimen to guarantee the safety and efficacy of the agent. For cancer prevention clinical research, the U.S. National Cancer Institute (NCI) traditionally has used a three-phase approach for testing chemoprevention agents. These potential chemoprevention agents are tested for safety and pharmacokinetic profiles in a small number of individuals (phase I trial); intermediate-endpoint biomarkers that are modulated by the agent and have potential to serve as surrogates for clinical disease endpoints are identified and tracked in trials with as many as several hundred individuals (phase II trial or a combination of phase I and phase II trials); and a large-scale, randomized, controlled trial is conducted to determine if the agent reduces cancer risk, the critical clinical endpoint in cancer prevention research (phase III trial). NCI encourages extensive follow-up to further evaluate the long-term safety and efficacy of an intervention. More than 150 potential chemopreventative agents have been identified in preclinical studies sponsored by the NCI's Division of Cancer Prevention (DCP), and development continues on the more than 40 agents that have shown evidence of safety and chemopreventative efficacy. Figure 1.1 depicts the approach of chemoprevention research and the stages in the carcinogenic process that may be targeted by chemopreventative agents.

An effort is being made at NCI to shorten the time an agent spends in the phased system, and